While Americans understand the benefits of GLP-1 agonist medications, 83% of Americans are unwilling to pay more than $100 in ...

Dual eligibility was a proxy for high social risk in a retrospective study that compared outcomes in that group with ...

The Arthritis Foundation is funding a study to help predict the onset and progression of interstitial lung disease in ...

AI apps that can detect skin cancer can be manipulated and potentially miss cases of melanoma, a serious skin cancer.

Ernst & Young study shows 85% of participating organization leaders are seeing better patient outcomes, and nearly 75% report ...

The pharmacy benefit manager (PBM) industry is under pressure to shift to models that avoid conflicts of interest and ...

As researchers continue to explore more effective solutions, combining platelet-rich plasma (PRP) with fractional laser ...

The United States has the highest maternal mortality rate of any high-income country, a crisis perpetuated by the lack of ...

Although 52% of healthcare leaders believe a fatal cyber-related patient incident will happen within the next five years, ...

Satellos Bioscience Chief Scientific Officer discusses early-stage trials of the company's Duchenne muscular dystrophy drug, ...

The approval is based on results from the phase 3 ARANOTE trial, which showed Nubeqa, when combined with androgen deprivation ...

Ernst & Young study shows 85% of participating organization leaders are seeing better patient outcomes, and nearly 75% report ...